SAINT-BRUNO-DE-MONTARVILLE, Quebec, April 27, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) announced today the completion of the previously announced transaction (the “Transaction with Financière Outremont”) with Colabor 2026 L.P., acting through its general partner 9563-0570 Québec Inc., a member of the group of Financière Outremont inc., pursuant to which Colabor 2026 L.P. has acquired substantially all of the assets of the Company and of its subsidiaries Norref Fisheries Quebec Inc. and Transport Paul-Émile Dubé Ltée. The closing of the Transaction with Financière Outremont marks the completion of the four transactions (collectively, the “Transactions”) contemplated by the previously announced definitive agreements (the “Definitive Agreements”) entered into in connection with the sale and...

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce that it will be reporting its financial results for the period ended March 31, 2026 (“Q1 2026”) after market close on Wednesday May 13, 2026.   The Company also advises that it has entered into an amendment to temporarily increase its $1.0 million line of credit agreement with Community Savings Credit Union (“CSCU” or the “Lender”) to $2.5 million (the “Amendment”). Q1 2026 Conference Call The Company will be hosting a conference call to discuss the results on Thursday, May 14, 2026. Conference call details are as follows:Time: 7:00...

ATHENS, Greece, April 27, 2026 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”) has scheduled its Annual Meeting of Shareholders for June 17, 2026, at 10:00 a.m. Eastern Time (the “Annual Meeting”). The record date for determining shareholders entitled to participate at the Annual Meeting is April 20, 2026. The business of the Annual Meeting is to (i) elect three Term III Directors to serve until the 2029 Annual Meeting of Shareholders, (ii) ratify the appointment of PricewaterhouseCoopers S.A., as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and (iii) to approve the Company’s Second Amended and Restated Articles of Incorporation and to authorize the Board of Directors to effect such amendment and restatement by filing the same with the Registrar of...

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on...

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-102 construct and provide translational support for the Part A REVEAL Phase 1/2 clinical data in patients with Rett syndrome DALLAS, April 27, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies...

Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. “We’re excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo’s science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich...

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission’s decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this...